Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
169
resultados
Última actualización
29/10/2026 [07:08:00]
Resultados 50 a 75 de 169
Resumen de: US20260308530A1
0000 Disclosed herein are compositions and methods to differentiate pancreatic cells into functional insulin-producing CD133/Ki-67-positive activated islet proliferating cells (AIPCs) derived from isolated pancreatic islets and expand derived-AIPCs in in vitro cultures using a culture medium comprising an active agent. Also disclosed herein is the use of the AIPCs for implantation into a mammal for in vivo therapy, specifically for pancreatic disorders, including diabetes type I.
Resumen de: WO2026211868A1
The present invention relates to an agent for improving the characteristics of a peptide and a method for improving the characteristics of a peptide. The present invention also relates to an α-glucosidase having the activity of binding D-glucose to an N-protective amino acid. The present invention also relates to a method for producing an amino acid glycoside. TThe present invention also relates to a method for producing an amino acid glycoside. The agent and method of the present invention utilize a single amino acid glycoside, or a dipeptide or tripeptide containing one or more amino acid glycosides. The α-glucosidase of the present invention has: (1) an amino acid sequence of SEQ ID NO: 11; (2) an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 11; or (3) an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 11. The α-glucosidase of the present invention has: (1) an amino acid sequence of SEQ ID NO: 14; (2) an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 14; or (3) an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 14. A method for producing amino acid glycosides of the present invention includes a step for generating amino acid glycosides by reacting a carbohydrate hydrolase that acts on amino acids or amino acid derivatives and binds D-glucose with a par
Resumen de: EP4817520A2
An example method for initializing a glucose sensor includes executing an initialization sequence for the glucose sensor, wherein the initialization sequence is based on one or more of parameters related to manufacturing the glucose sensor or environmental conditions of the glucose sensor that are present in vivo, and reporting glucose levels in a patient after the initialization sequence.
Resumen de: WO2025117799A1
Embodiments described herein gradually shift a basal rate pattern for a user in time when the time on an insulin pump is changed and use glucose levels from a CGM sensor to coordinate the shift in the basal pattern with the user's actual glucose response to the changing parameters to safely transition the timing of the basal pattern as quickly as possible.
Resumen de: US20250170330A1
0000 Disclosed herein are systems and methods for closed loop and/or partial and/or hybrid closed loop therapy that can provide adaptive personal profiles for when glucose levels are not available and/or unreliable from a continuous glucose monitor (CGM), such as, for example, during a warmup period of the CGM sensor. The profile can include temporary delivery profile such as a CGM warmup profile that is activated specifically for the particular scenario and is designed to minimize the risk of blood glucose fluctuations until the glucose levels are available and reliable, such as when the CGM sensor is warmup up and closed loop therapy based on the sensor can be activated.
Resumen de: WO2025117512A1
A continuous analyte monitoring system includes first and second analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller Is coupled to the analyte sensors and configured evaluate first samples of outputs of the first analyte sensor and second samples of outputs of the second analyte sensor with respect to one another to determine whether the first samples and the second samples indicate compression of the tissue. If the first samples and the second samples indicate compression of the tissue, compensate for the compression of the tissue with respect to the first samples. The controller may evaluate the machine learning models using a machine learning model or a filter.
Resumen de: MX2025002639A
The present invention describes a method for detecting chronic kidney disease (ERC) in samples from subjects with type 2 diabetes (DT2) by metabolic analysis. This method is based on two approaches: a panel of metabolite/creatinine (met/Cr) ratios and a statistical model developed from the spectral profile obtained by hydrogen nuclear magnetic resonance (1H NMR). The method was tested in a cohort of samples from subjects with type 2 diabetes in order to identify renal damage in early stages. The directed metabolomica allows to evaluate the metabolite/creatinine ratio, while the non-targeted metabolomica, based on the 1H NMR spectrum, facilitates initial ERC prediction by statistical analysis and identification of the most affected metabolic pathways. This invention makes it possible to differentiate stadiums from chronic kidney disease and even detect their presence in subjects without obvious symptoms. Its efficacy is supported with a sensitivity of 1,000 and a specificity of 0.895 in the control group, demonstrating its high yield in early identification of the disease. This advancement offers an innovative tool for improving the detection and treatment of CKD in diabetic subjects.
Resumen de: MX2026005362A
The present invention relates to a device for storing and loading inputs necessary for the injection of a medicament among others insulin and is a functional and ergonomic redesign of an insulin injection pen, specifically directed to older adult persons suffering from diabetes or another disease requiring the application of a medicament and presenting articular conditions such as arthritis. This design arises in response to physical limitations facing this group of users by using conventional devices, especially as regards the placement of the needle, the application of force and the precision in handling. The proposal incorporates an assisted mechanism that facilitates insertion of the needle without requiring complex movements, thereby guaranteeing greater comfort, safety and autonomy for the user. In addition, the device has an integrated cooling system that keeps the insulin at a suitable temperature, ensuring the preservation of the drug under optimal conditions. Also included is an automated injection mechanism that allows administering the dose with only pressing a side button of good size, especially designed for hands with reduced mobility. This design seeks not only to improve the use experience, but also contribute significantly to the comfortable and easy handling for people with muscular mobility limitations such as arthritis.
Resumen de: WO2026202693A1
A system, device, and method for treating a diabetic condition are provided. An illustrative device includes: a lead connectable to a signal generator and including a plurality of electrodes, wherein the plurality of electrodes generate a stimulation signal according to an input received from the signal generator and deliver the stimulation signal to one or more anatomical elements of a patient to treat at least one aspect of a diabetic condition based on a closed feedback loop.
Resumen de: WO2026207251A1
The present disclosure provides systems, methods, compositions, and algorithms for treating a subject diagnosed with a glucose hypometabolic disorder (e.g., Alzheimer's disease, Parkinson's disease, or heart failure).
Resumen de: US20260301941A1
0000 Methods and systems for encouraging interactions with a glucose monitoring system include incrementing a score and/or providing a reward based on a variety of different interactions with the glucose monitoring system. The interactions which improve the score may include initiating or changing displays, downloading data, setting operational parameters and other interactions that are independent of a user's glucose measurements. Encouraging these interactions can enhance success in maintaining healthy glucose concentrations.
Resumen de: US20260297530A1
0000 The invention features cells, islet-like cells, pancreatic islets and organoids (e.g., human islet-like organoids or HILOs), as well as cell cultures and methods that are useful for the rapid and reliable generation of cells and organoids, such as pancreatic islets and organoids, that are sustainable in vivo and that evade immune detection, rejection and autoimmunity. The invention also features methods of treating pancreatic diseases, such as type 2 diabetes, and pancreatic cancer, using the cells, islet-like cells, pancreatic islets and organoids (e.g., HILOs) that are designed to modulate the activity of immune cells that would otherwise react against them.
Resumen de: US20260294287A1
A continuous glucose monitor (CGM) sensor includes a glucose oxidation electrode and a counter electrode, and does not include a glucose-specific enzyme. The glucose oxidation electrode includes a nanoporous layer comprising metal nanoparticles. The CGM sensor generates an electrical signal indicative glucose oxidation in a liquid containing glucose, which has a correlation with an effective surface area of the metal nanoparticles in the nanoporous layer. When the CGM sensor is implanted in a subject's body, an AC voltage is applied between the glucose oxidation electrode and the counter electrode, and impedance is obtained. A glucose level for the subject is determined using the impedance without use of information or data related to glucose sensitivity of a sensor or sensors over use or time.
Resumen de: US20260294345A1
Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. The microneedle array may include, for example, at least one microneedle including a tapered distal portion having an insulated distal apex, and an electrode on a surface of the tapered distal portion located proximal to the insulated distal apex. At least some of the microneedles may be electrically isolated such that one or more electrodes is individually addressable.
Resumen de: US20260294290A1
According to the present disclosure, an applicator for a continuous blood glucose measurement device, the applicator being operated by attaching a body attachment unit to the body of a user, the body attachment unit including a sensor member which is inserted into the body of the user in order to measure the blood glucose, comprises: a main case; a plunger to which the body attachment unit is detachably coupled and which is installed in the main case to be movable from a first position to a second position so that the body attachment unit can be discharged to the outer direction of the main case; a needle which is detachably coupled to the body attachment unit so as to be inserted into the body of the user along with the sensor member; and a needle separating unit which separates the needle from the body of the user by moving the needle in the direction opposite to the discharge direction of the plunger, wherein the needle separating unit includes a locking unit which can be assembled with the plunger in the manner of being engaged with one side of the plunger.
Resumen de: US20260297540A1
0000 One aspect of the embodiments relates to a cell preservation solution, comprising: 20 mM~50 mM of sucrose; 20 mM~50 mM of mannitol, 10 mM~50 mM of lactobionic acid, 5 mM~20 mM of glucose, 1 mM~3 mM of adenosine, 1 mM~5 mM of reduced glutathione, 1 mM~2 mM of dextran-40, 10 mM~30 mM of potassium dihydrogen phosphate, 10 mM~30 mM of potassium carbonate, 10 mM~30 mM of potassium chloride, 5 mM~30 mM of sodium chloride, 10 mM~60 mM of sodium hydroxide, 10 mM~60 mM of potassium hydroxide, 0 mM~20 mM of vitamin E, 0 mM~25 mM of 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, and 0%~10% dimethyl sulfoxide. Another aspect of the embodiments relates to a cell preservation method, which uses the cell preservation solutions described in the present application to store cells.
Resumen de: US20260294352A1
0000 Embodiment relate to a system for developing a model to classify continuous glucose monitoring (CGM) data. The system includes a processor and computer memory having instructions stored thereon that when executed will cause the processor to determine whether two CGM profiles match based on a similarity of shapes of the two CGM profiles, each CGM profile including a data set of CGM measurements. The processor designates two matching CGM profiles as a CGM profile pair. The processor transforms the CGM profile pair into a motif. The processor labels the motif as a labelled motif based on a clinical characteristic. The processor recursively repeats the determine, designate and transform steps of a CGM profile pairing process until a finite set of motifs is created, which includes the labelled motif as a classified data point. The processor monitor, analyzes, or influences a concentration of glucose levels in a fluid.
Resumen de: US20260295161A1
Disclosed herein are techniques related to delivery of correction boluses. In some embodiments, the techniques involve obtaining data indicative of an ongoing glycemic response to a meal. The data includes glucose concentration measurements evaluated in combination with one or more insulin concentration values. The techniques further include causing delivery of one or more correction doses to at least partially counteract the ongoing glycemic response to the meal. The one or more correction doses are delivered instead of or in addition to a meal bolus delivered for the meal.
Resumen de: US20260295160A1
Disclosed herein are systems and methods for automated insulin delivery that provide for adaptive closed loop control that can modify the stored basal profile used by the closed loop algorithm to better reflect the user's actual needs. Actual delivery rates calculated by the closed loop algorithm can be compared to the user's stored profile. If the differences between the actual delivery rates and the stored profile are statistically significant, the stored profile can be modified.
Resumen de: WO2026206023A1
Disclosed is a photoacoustic measurement method for quantitatively measuring components of a sample by using a laser pulse having a prescribed wavelength and an ultrasonic sensor having a prescribed frequency band. The photoacoustic measurement method may comprise the steps of, when the incident position of a laser pulse, the beam width of the laser pulse, and the relative position of an ultrasonic sensor are determined from the given frequency band of the ultrasonic sensor and the given position of a photoacoustic region in a sample: (a) oscillating the laser pulse with prescribed pulse energy and a prescribed pulse width to be incident onto the photoacoustic region in the sample; (b) detecting, by means of the ultrasonic sensor, photoacoustic waves generated in the photoacoustic region in the sample by the incident laser pulse, and acquiring sampling data by sampling the waveforms of the detected photoacoustic waves at a prescribed sampling rate; and (c) storing the sampling data. Furthermore, the distance from the photoacoustic region to the ultrasonic sensor may be determined on the basis of the wavelength of a frequency belonging to the frequency band of the ultrasonic sensor, and the beam width of the laser pulse may be determined on the basis of the half wavelength of the maximum frequency belonging to the frequency band of the ultrasonic sensor.
Resumen de: WO2026206121A1
A photoacoustic measurement device of the present invention comprises a first housing and a second housing. The first housing accommodates a light source. The second housing accommodates an ultrasonic sensor and is in acoustic contact with the first housing. The characteristic acoustic impedance of a first material constituting the first housing is greater than the characteristic acoustic impedance of a second material constituting the second housing. The first housing further includes an opening through which light generated by the light source is emitted. The second housing further includes an optical path through which the light generated by the light source is guided. The optical path of the second housing is formed in a direction in which the light travels from the opening of the first housing.
Resumen de: WO2026206022A1
The present disclosure provides a photoacoustic measurement method capable of measuring a component of a sample by using photoacoustic waves generated by a laser pulse having a predetermined wavelength. The photoacoustic measurement method may comprise the steps of: oscillating a laser pulse at a predetermined pulse energy and pulse width and causing the laser pulse to be incident toward a photoacoustic generation area within the sample, with an ultrasonic sensor being disposed adjacent to the incident position of the laser pulse in accordance with a predetermined geometry defined by a beam width and incident position of the laser pulse with respect to the sample, the center of the photoacoustic generation area in the sample, and the position of the ultrasonic sensor; detecting, by the ultrasonic sensor, within a predetermined frequency band, photoacoustic waves generated by the laser pulse in the photoacoustic generation area in the sample, and sampling a waveform of the detected photoacoustic waves at a predetermined sampling rate to obtain sampling data; and storing the sampling data.
Resumen de: US20260295150A1
0000 A method for administering medicament from a medical device includes receiving, from a sensor, a first biomarker level in a user, determining a basal rate of endogenous glucose production based on one or more biomarker levels, determining, based on the basal rate, an amount of medicament to transfer to the user, transmitting a first instruction to the medical device to deliver the amount of medicament to the user, further receiving, from the sensor, a second biomarker level in the user, adjusting the basal rate based on the first biomarker level and the second biomarker level, adjusting the amount of medicament to transfer to the user based on the adjusted basal rate, and transmitting a second instruction to the medical device to deliver the amount of medicament to the user.
Resumen de: WO2026206158A1
The present invention relates to a device for assisting in the prevention of ulcers, consisting of footwear having interchangeable cells where the plantar pressure is measured in individual areas of the sole of the foot by means of force sensors and sent via Bluetooth to be displayed in an application. The areas at risk of ulceration are thus detected and the cell is removed in order to facilitate plantar distribution, without the risk of developing diabetic foot.
Nº publicación: US20260294292A1 01/10/2026
Solicitante:
SENSEONICS INCORPORATED [US]
Senseonics, Incorporated
Resumen de: US20260294292A1
0000 A sensor (e.g., an analyte sensor) that may be implanted partially or fully within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a housing including one or more indicator portions, a plurality of drug portions on opposite sides of each indicator portion, circuitry within the housing, including a sensing area, analyte indicator material, and a plurality of drug-eluting material in or on the drug portions of the exterior surface of the housing. The drug-eluting material each comprise one or more therapeutic agents that reduce deterioration of the analyte indicator material.
BOPI
Sede Electrónica
